ArticleInflammopharmacology2025
Gastroprotective effect of Arabincoside B isolated from Caralluma arabica against ethanol-induced gastric injury via modulating oxidative stress/SP/NK-1R/NF-κB loop.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The SP-MrgprX2 Axis in Allergic Rhinitis: a Neuro-immune Paradigm Beyond IgE-mediated Inflammation.Clinical reviews in allergy & immunology · 2026Review
- Aspirin Eugenol Ester Alleviates Gastric Injury by Inhibiting Ferroptosis and Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric ulcer is a common gastrointestinal condition. Arabincoside B (AR-B), a pregnane glycoside isolated from the aerial parts of Caralluma arabica, shows multiple pharmacological effects. This study aimed to investigate the gastroprotective therapeutic effects of AR-B in ethanol-induced gastric injury in rats. Rats were divided as follows: Group I (NC): received 1 mL/day of normal saline; Group II (PC): received distilled water then 95% ethanol (1 mL per rat) after 1 h; Group III (FAM): received oral famotidine (20 mg/kg); Groups IV and V (AR-B groups): received 25 and 50 mg/kg of AR-B, respectively. Treatments (FAM or AR-B) were administered 1 h prior to ethanol. The rats were killed after 1 h after ethanol administration. Gross inspections as well as histopathological assessment of stomach tissues of untreated ethanol-only treated rats revealed major alterations as compared to those of normal rats. Pretreatment with AR-B showed enhancement in the gross and histological alterations. Moreover, AR-B at the dose of (50 mg/kg) possessed superior anti-inflammatory and antioxidant effects. This was confirmed by a significant lowering of the serum IL-6 and TNF-α levels, decreasing p-NF-κB gastric expression, decreasing MDA, and increasing GSH gastric levels. Furthermore, AR-B caused a significant increase in TFF-2 and MUC-6 stomach tissue expression, preserving the gastric mucosa. In addition, gastric expression of substance P and NK-1R was decreased, which participated in the reduction of inflammation. The current research highlights the gastroprotective impact of AR-B especially at a dose of (50 mg/kg), suggesting its future role in preventing recurrence in peptic ulcer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.